Feb. 4 at 2:32 AM
$TTOO to answer my own question(s)
CRG is still owed ~
$10MM in debt, to my knowledge, so they still own the lien on the patents through this outstanding debt, despite an exited equity position (per CRG website)
So if a deal was not reached, and T2 is “winding down”, it appears CRG will walk away with the patents and common shareholders in T2 Biosystems will be… I have no clue…?
CRG however gets to sit on patents that don’t expire for 5-15 years, to my knowledge, untethered to the structure that was T2 Biosystems/shareholders
Lmfao “capitalism”